Skip to main content

Table 2 Patient survival according to BCLC stage and treatment

From: Octreotide treatment of patients with hepatocellular carcinoma - a retrospective single centre controlled study

   BCLC A BCLC B
   number median survival (months) log rank test number median survival (months) log rank test
number treatment modalities   40    55   
  Sandostatin LAR 11 31.4 P = 0.35038 14 22.4 P = 0.00003
  TACE 5 37.3   9 22.0  
  multimodal therapy 7 40.2   10 35.5  
  palliative care 17 15.1   22 2.9